CervoMed

CervoMed is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders, primarily dementia with Lewy bodies (DLB) and Alzheimer's disease. Their lead product candidate, neflamapimod, is an oral, selective small molecule inhibitor of the protein kinase p38 alpha, which they believe is a key driver of synaptic dysfunction, a reversible aspect of the neurodegenerative process. Neflamapimod is currently in clinical development for DLB and Alzheimer's disease, and preclinical data suggests its potential for stroke recovery.

CervoMed is headquartered in Boston, Massachusetts and has assembled a highly experienced leadership team with expertise in drug development, clinical trials, and commercialization. They have a strong scientific advisory board composed of renowned experts in neurodegenerative diseases. CervoMed is committed to developing innovative drug treatments for a range of central nervous system disorders, with a focus on addressing the urgent need for effective therapies for DLB and Alzheimer's disease.

CervoMed is a clinical-stage biotechnology company committed to developing and commercializing drug treatments for neurodegenerative diseases, particularly those affecting the brain's synapses. The company believes that early intervention in the neurodegenerative process can reverse synaptic dysfunction and slow or prevent disease progression, ultimately improving the lives of patients suffering from debilitating conditions like dementia with Lewy bodies and Alzheimer's disease. Their primary focus is on the development of neflamapimod, an orally administered small molecule that inhibits the enzyme p38 alpha, a key driver of synaptic dysfunction.

CervoMed promotes a culture of innovation and collaboration, focused on developing life-changing treatments for neurodegenerative diseases. They prioritize a strong scientific foundation and a patient-centric approach. Their website highlights the passion and expertise of their team, emphasizing their commitment to making a positive impact on the lives of individuals affected by these conditions. This translates into a workplace that values scientific rigor, collaboration, and a shared sense of purpose.